# Tofacitinib: A Promising Therapeutic Option for Refractory Pityriasis Rubra Pilaris—A Case Report

## TL;DR

Tofacitinib, a JAK inhibitor, successfully treated a patient with refractory Pityriasis Rubra Pilaris, a rare and severe skin disorder.

## Contribution

This case report demonstrates the effectiveness of tofacitinib in treating refractory PRP, offering a new therapeutic option.

## Key findings

- Tofacitinib successfully treated a patient with refractory PRP.
- JAK inhibitors may be a promising treatment for severe PRP cases.

## Abstract

Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disorder that can severely impact the quality of life in patients, particularly when presenting in chronic or refractory form. Emerging evidence suggests that JAK inhibitors may offer a potential treatment option. Here, we present a case of refractory PRP successfully treated with tofacitinib.